AstraZeneca will pay Quell Therapeutics $85 million upfront for it to help develop treatments for autoimmune diseases, and further payments of more than $2 billion for future development and commercial milestones and royalties.
AstraZeneca will pay Quell Therapeutics $85 million upfront for it to help develop treatments for autoimmune diseases, and further payments of more than $2 billion for future development and commercial milestones and royalties.